Johnson & Johnson to acquire Abiomed in $16.6B deal
Johnson & Johnson agreed to acquire heart-support device maker Abiomed through a tender offer at $380 per share in cash plus a contingent value right of up to $35 per share, an enterprise value of about $16.6 billion.
